BridgeBio Pharma, Inc. (NASDAQ: BBIO) announced that its investigational drug encaleret demonstrated normalization of blood and urine calcium levels in ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE